The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
The hepatitis C virus care cascade in the New York City jail system during the direct acting antiviral treatment era, 2014-2017
EClinicalMedicine. 2020 Oct 5;27:100567. doi: 10.1016/j.eclinm.2020.100567.eCollection 2020 Oct.
Justin Chan1, Fatos Kaba1, Jessie Schwartz2, Angelica Bocour2, Matthew J Akiyama3, Zachary Rosner1, Ann Winters2, Patricia Yang1, Ross MacDonald1
Author information
1Correctional Health Services, NYC Health + Hospitals, 55 Water Street, 18th floor, New York, NY 10041, United States.
2Bureau of Communicable Diseases, Viral Hepatitis Program, New York City Department of Health and Mental Hygiene, Long Island City, NY 11101, United States.
3Montefiore Medical Center, Albert Einstein College of Medicine, 1621 Eastchester Road, Bronx, NY 10461, United States.
Abstract
Background: High patient turnover presents challenges and opportunity to provide hepatitis C virus (HCV) care in US jails (remand facilities). This study describes the HCV care cascade in the New York City (NYC) jail system during the direct-acting antiviral (DAA) treatment era.
Methods: Patients admitted to the NYC jail system from January 2014 through December 2017 were included in this retrospective cohort analysis. We describe rates of screening, diagnosis, linkage to jail-based care, and treatment among the overall cohort, and among subgroups with long jail stays (≥120 days) or frequent stays (≥10 admissions). The study protocol was approved by a third-party institutional review board (BRANY, Lake Success, NY).
Findings: Among the 121,371 patients in our analysis, HCV screening was performed in 40,219 (33%), 4665 (12%) of whom were viremic, 1813 (39%) seen by an HCV clinician in jail, and 248 (5% of viremic patients) started on treatment in jail. Having a long stay (adjusted risk ratio [aRR] 8·11, 95% confidence interval [CI] 6·98, 9·42) or frequent stays (aRR 1·51, 95% CI 1·04, 2·18) were significantly associated with being seen by an HCV clinician. Patients with long stays had a higher rate of treatment (14% of viremic patients). Sustained virologic response at 12 weeks was achieved in 147/164 (90%) of patients with available virologic data.
Interpretation: Jail health systems can reach large numbers of HCV-infected individuals. The high burden of HCV argues for universal screening in jail settings. Length of stay was strongly associated with being seen by an HCV clinician in jail. Treatment is feasible among those with longer lengths of stay.